By: Adam Feuerstein | 06/02/14 - 03:20 PM EDT
It's me again, still reporting from the American Society of Clinical Oncology (ASCO) annual meeting. We just got our first look at the clinical activity of
(INCY) immuno-oncology candidate INCB024360 ('360) dosed at 50 mg and combined with
(BMY) Yervoy in melanoma patients. The Wall Street scrum around the Incyte poster was insane.
$INCY IDO poster scrum. #ASCO14 pic.twitter.com/yAk04mYGJ5 Adam Feuerstein (@adamfeuerstein) June 2, 2014Oh yeah, you're probably interesting in hearing about the data. Four immunotherapy-naive melanoma patients dosed with 50 mg of '360 plus Yervoy yielded 1 complete response and 1 partial response for an overall response rate of 50%. A third patient reported stable disease so the disease control rate was 75%. The Incyte press release and poster can be found here.
10/21/14 - 09:29 AM EDT
10/20/14 - 10:56 AM EDT
10/15/14 - 04:07 PM EDT
10/14/14 - 10:53 AM EDT
10/08/14 - 03:52 PM EDT
10/21/14 - 11:34 AM EDT
10/21/14 - 10:23 AM EDT
10/21/14 - 09:59 AM EDT
10/20/14 - 11:57 AM EDT
10/20/14 - 11:33 AM EDT
Access the tool that DOMINATES the Russell 2000 and the S&P 500.